GlassScriptPhysician profile
Matthew Barnett
NPI 1013953157
$6,824.90
in general payments reported to CMS, 2019-2025
40 companies · $666 in 2025
The $666 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,077 · 2020: $760 · 2021: $854 · 2022: $971 · 2023: $1,176 · 2024: $1,321 · 2025: $666.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,163.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,163.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $732.96 | 2019-2025 | |
| Abbvie INC. | $677.95 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $577.90 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $531.71 | 2021-2025 | Mounjaro, Zepbound, Emgality |
| Astellas Pharma US INC | $383.51 | 2019-2025 | Veozah |
| Amgen INC. | $370.61 | 2019-2025 | Evenity, Prolia, Repatha |
| Janssen Pharmaceuticals, INC | $302.59 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $275.49 | 2019-2025 | Trintellix |
| Glaxosmithkline, LLC. | $270.44 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $269.52 | 2019-2024 | Synjardy, Jardiance |
| Novartis Pharmaceuticals Corporation | $258.30 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $248.47 | 2019-2025 | Xifaxan, Trulance |
| Merck Sharp & Dohme LLC | $233.52 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Abbott Laboratories | $228.07 | 2022-2025 | Freestyle Libre 3, Assurity |
| Astrazeneca Pharmaceuticals LP | $217.19 | 2020-2025 | Breztri, Airsupra |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Barnett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.